Page 47 - ESGO - Vulvar cancer - Complete report_fxd2

Table 15. Original studies presenting data in recurrent patients treated with chemotherapy alone

Authorreference Year N Chemotherapy regimen Response Survival

Witteveen et al.267 2009 29 Tax 175 mg/m² IV q3 weeks; up to 9 cycles ORR: 13.8% (4/29) Median PFS: 2.6 months
CR: 6% (2/29) Median OS: 6.8 months
PR: 6% (2/29)
NA
Thigpen et al.268 1986 22 CisP 50 mg/m² IV q3 weeks ORR: 0%
CR: 0% Median PFS: 10 months
PR: 0% Median OS: 19 months

Cormio et al.269 2009 15 CisP 80 mg/m2 IV d1 + Vinorelbine 25 mg/m² IV d1 and d8, ORR: 40% (6/15) PFS: NA
OS: NA
q21 d for up to 6 cycles CR: 27% (4/15)
Median follow-up: 8 months
PR: 13% (2/15) Median PFS: 4.8 monthsa
Median OS: 7.8 monthsa
Thigpen et al.268 1986 13 Piperazinedione 9 mg/m² IV q3 weeks ORR: 0%
CR: 0%
PR: 0%

Wagenaar et al.259 2001 13 Week 1: Bleo 5 mg IM d1-5 + CCNU 40 mg PO d5-7 + MTX 10 ORR: 54% (7/13)
mg PO d1+4
Weeks 2-6: Bleo 5 mg IM d1 + 4 + MTX 15 mg PO d1.

Muss et al.270 1989 11 Mitoxantrone 12 mg/m² IV q3 weeks ORR: 0% Median PFS: 1.3 months
Durrant et al.257 CR: 0% Median OS: 3.2 months
PR: 0%
PFS: NA
1990 11 Bleo 5 mg IM d1–5 + MTX 15 mg PO d1 and 4 + CCNU 40 mg ORR: 60% (6/10) OS: NA

PO d5-7 week 1, then Bleo 5 mg IM d1 and 4 + MTX 15 mg PO CR : NA

d1 and 4 weeks 2-5 PR : NA

Han et al.264 2012 2 Tax 60 mg/m² IV + Carbo AUC 2.7 IV weekly ORR = 0% Mean follow-up: 3.5 months
PFS: -
OS: NA

a median survival among 12 patients with primary locally advanced disease and 13 with locoregional recurrence (data not available for patients with locoregional
recurrence specifically), Bleo bleomycin, Carbo: carboplatin, CCNU: lomustine, CisP: cisplatin, CR: complete response, LAVC: locally advanced vulvar cancer,
NA: not available, ORR: overall response rate, OS: overall survival, PR: partial response, PFS: progression-free survival, MTX: methotrexate, Tax: paclitaxel.

 VULVAR CANCER - GUIDELINES 
47